6LJ Stock Overview
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Matinas BioPharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.15 |
| 52 Week High | US$0.65 |
| 52 Week Low | US$0.096 |
| Beta | 1.55 |
| 1 Month Change | -35.26% |
| 3 Month Change | -1.39% |
| 1 Year Change | -74.33% |
| 3 Year Change | -79.74% |
| 5 Year Change | -83.82% |
| Change since IPO | -95.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6LJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -1.2% | 1.7% |
| 1Y | -74.3% | -23.0% | 2.3% |
Return vs Industry: 6LJ underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 6LJ underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 6LJ volatility | |
|---|---|
| 6LJ Average Weekly Movement | 25.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6LJ's share price has been volatile over the past 3 months.
Volatility Over Time: 6LJ's weekly volatility has decreased from 66% to 26% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 32 | Jerry Jabbour | www.matinasbiopharma.com |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
Matinas BioPharma Holdings, Inc. Fundamentals Summary
| 6LJ fundamental statistics | |
|---|---|
| Market cap | €42.54m |
| Earnings (TTM) | -€21.44m |
| Revenue (TTM) | €1.02m |
41.6x
P/S Ratio-2.0x
P/E RatioIs 6LJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6LJ income statement (TTM) | |
|---|---|
| Revenue | US$1.10m |
| Cost of Revenue | US$12.37m |
| Gross Profit | -US$11.27m |
| Other Expenses | US$11.67m |
| Earnings | -US$22.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | -1,028.56% |
| Net Profit Margin | -2,093.25% |
| Debt/Equity Ratio | 0% |
How did 6LJ perform over the long term?
See historical performance and comparison